Companies
MedChemExpress LLC (MCE)
Products
MedChemExpress - Model Idactamab - ...

MedChemExpress - Model Idactamab - 2245205-37-0

Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5)[1][2].

Idactamab

MCE China：Idactamab

Brand：MedChemExpress (MCE)

Cat. No.HY-P99654

CAS：2245205-37-0

Synonyms：INT-001

Purity：95.00%

Storage：Please store the product under the recommended conditions in the Certificate of Analysis.

Shipping：Shipping with dry ice.

Description：Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5).

In Vitro：Idactamab inhibits different heme cancer cell lines with IC50 of 0.05-65 ng/mL[1].ASCT2 (SLC1A5) is a multi-pass, Na+-dependent neutral amino acid transporter that mediates the uptake of amino acids required for tumor growth and progression[1].

In Vivo：Idactamab improves 3 disseminated Acute Myeloid Leukemia (AML) cell line models: The survival rates of TF1α (high expression of ASCT2), MOLM-13 (low expression of ASCT2) and M.V.411 (high expression of ASCT2) were 0.05 mg/kg, 0.1 mg/kg, and 0.1 mg/kg, respectively[2].

IC50 & Target：ASCT2 (SLC1A5)[1] In Vitro Idactamab inhibits different heme cancer cell lines with IC50 of 0.05-65 ng/mL[1].ASCT2 (SLC1A5) is a multi-pass, Na+-dependent neutral amino acid transporter that mediates the uptake of amino acids required for tumor growth and progression[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Idactamab Related Antibodies

Species：Human

Isotype：Human IgG1 kappa

Recommend Isotype Controls：Human IgG1 kappa, Isotype Control

References：

[1]. Pore N, et al. Discovery and development of MEDI7247, a novel pyrrolobenzodiazepine (PBD)-based antibody drug conjugate targeting ASCT2, for treating hematological cancers[J]. Blood, 2018, 132: 4071.

[2]. Monks N R, et al. Abstract LB-295: MEDI7247, a novel pyrrolobenzodiazepine ADC targeting ASCT2 with potent in vivo activity across a spectrum of hematological malignancies[J]. Cancer Research, 2018, 78(13_Supplement): LB-295-LB-295.

Brand introduction:
•   MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
•   More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
•   The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
•   Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
•   It has a professional experimental center and strict quality control and verification system；
•   Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
•   The biological activity of the products has been verified by the experiments of customers in various countries；
•   A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
•   Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
•   It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。